Cargando…

TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes

Decrease in DNA dioxygenase activity generated by TET2 gene family is crucial in myelodysplastic syndromes (MDS). The general downregulation of 5-hydroxymethylcytosine (5-hmC) argues for a role of DNA demethylation in MDS beyond TET2 mutations, which albeit frequent, do not convey any prognostic sig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gurnari, Carmelo, Pagliuca, Simona, Guan, Yihong, Adema, Vera, Hershberger, Courtney E., Ni, Ying, Awada, Hassan, Kongkiatkamon, Sunisa, Zawit, Misam, Coutinho, Diego F., Zalcberg, Ilana R., Ahn, Jae-Sook, Kim, Hyeoung-Joon, Kim, Dennis Dong Hwan, Minden, Mark D., Jansen, Joop H., Meggendorfer, Manja, Haferlach, Claudia, Jha, Babal K., Haferlach, Torsten, Maciejewski, Jaroslaw P., Visconte, Valeria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Stimulus Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753204/ https://www.ncbi.nlm.nih.gov/pubmed/34768283 http://dx.doi.org/10.1182/bloodadvances.2021005418

Ejemplares similares

Vacuolization of hematopoietic precursors: an enigma with multiple etiologies
por: Gurnari, Carmelo, et al.
Publicado: (2021)

A non‐cytotoxic regimen of decitabine to treat refractory T‐cell large granular lymphocytic leukemia
por: Zawit, Misam, et al.
Publicado: (2021)

Clinical and basic implications of dynamic T cell receptor clonotyping in hematopoietic cell transplantation
por: Pagliuca, Simona, et al.
Publicado: (2021)

Novel Scheme for Defining the Clinical Implications of TP53 Mutations in Myeloid Neoplasia
por: Bahaj, Waled, et al.
Publicado: (2023)

Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia
por: Bahaj, Waled, et al.
Publicado: (2023)

Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia
por: Guan, Yihong, et al.
Publicado: (2022)

Large Granular Lymphocytic Leukemia: From Immunopathogenesis to Treatment of Refractory Disease
por: Zawit, Misam, et al.
Publicado: (2021)

Genomics of deletion 7 and 7q in myeloid neoplasm: from pathogenic culprits to potential synthetic lethal therapeutic targets
por: Mori, Minako, et al.
Publicado: (2023)

A multimodal analysis of genomic and RNA splicing features in myeloid malignancies
por: Durmaz, Arda, et al.
Publicado: (2023)

Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes
por: Meggendorfer, Manja, et al.
Publicado: (2017)

Detection of ABL1 kinase domain mutations in therapy-naïve BCR-ABL1-positive acute lymphoblastic leukemia
por: Baer, Constance, et al.
Publicado: (2021)

Complex Landscape of Alternative Splicing in Myeloid Neoplasms
por: Hershberger, Courtney E., et al.
Publicado: (2020)

Personalized Risk Schemes and Machine Learning to Empower Genomic Prognostication Models in Myelodysplastic Syndromes
por: Awada, Hussein, et al.
Publicado: (2022)

Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q
por: Adema, Vera, et al.
Publicado: (2022)

Molecular characterization of AML with RUNX1-RUNX1T1 at diagnosis and relapse reveals net loss of co-mutations
por: Höllein, Alexander, et al.
Publicado: (2019)

Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies
por: Stengel, Anna, et al.
Publicado: (2021)

Clinical application of whole transcriptome sequencing for the classification of patients with acute lymphoblastic leukemia
por: Walter, Wencke, et al.
Publicado: (2021)

Specific subtype distribution with impact on prognosis of TP53 single-hit and double-hit events in AML and MDS
por: Stengel, Anna, et al.
Publicado: (2023)

S161: UBA1 NON-M41 VARIANTS ARE MORE AGGRESSIVE THAN UBA1 M41 VARIANTS IN THEIR HEMATOLOGICAL MANIFESTATIONS.
por: Sakuma, Maki, et al.
Publicado: (2023)

P690: IDENTIFICATION OF CLINICALLY RELEVANT VARIANT-LEVEL SEX-BIAS IN SF3B1 K700/K666 AND IDH2 R140/R172
por: Sakuma, Maki, et al.
Publicado: (2023)

“Somatic” and “pathogenic” - is the classification strategy applicable in times of large-scale sequencing?
por: Baer, Constance, et al.
Publicado: (2019)

Aberrant somatic hypermutation of CCND1 generates non-coding drivers of mantle cell lymphomagenesis
por: Müller, Heiko, et al.
Publicado: (2022)

SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis
por: Huber, Sandra, et al.
Publicado: (2022)

SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase
por: Huber, Sandra, et al.
Publicado: (2022)

P689: CLASSIFICATION OF MDS AND AML BASED SOLELY ON GENETICS OMITTING BLAST COUNTING – A WAY TO RESOLVE THE DISCREPANCIES BETWEEN CLASSIFICATIONS ACCORDING TO WHO AND ICC?
por: Haferlach, Claudia, et al.
Publicado: (2023)

COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP
por: Busca, Alessandro, et al.
Publicado: (2022)

Current status of intralesional agents in treatment of malignant melanoma
por: Zawit, Misam, et al.
Publicado: (2021)

AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics
por: Fuhrmann, Irene, et al.
Publicado: (2022)

MDS subclassification—do we still have to count blasts?
por: Huber, Sandra, et al.
Publicado: (2023)

Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS
por: Stengel, Anna, et al.
Publicado: (2023)

Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies
por: Sakuma, Maki, et al.
Publicado: (2023)

Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia
por: Gurnari, Carmelo, et al.
Publicado: (2020)

The Interactome between Metabolism and Gene Mutations in Myeloid Malignancies
por: Gurnari, Carmelo, et al.
Publicado: (2021)

Molecular Targeted Therapy in Myelodysplastic Syndromes: New Options for Tailored Treatments
por: Pagliuca, Simona, et al.
Publicado: (2021)

Alternative Splicing in Myeloid Malignancies
por: Gurnari, Carmelo, et al.
Publicado: (2021)

Mutations in spliceosome genes in myelodysplastic neoplasms and their association to ring sideroblasts
por: Huber, Sandra, et al.
Publicado: (2022)

AML classification in the year 2023: How to avoid a Babylonian confusion of languages
por: Huber, Sandra, et al.
Publicado: (2023)

P694: RISK ASSESSMENT ACCORDING TO IPSS-M IS SUPERIOR TO AML ELN 2022 RISK CLASSIFICATION IN MDS/AML PATIENTS DEFINED BY ICC – IS AN INCLUSION INTO AML TRIALS JUSTIFIED?
por: Huber, Sandra, et al.
Publicado: (2023)

P1213: ARTIFICIAL INTELLIGENCE TO PREDICT MEDICAL DIAGNOSIS FROM FLOW CYTOMETRIC RAW DATA IN MATURE B-CELL AND T-CELL NEOPLASMS, AML, ALL, MDS AND MULTIPLE MYELOMA
por: Müller, Martha-Lena, et al.
Publicado: (2023)

Dissemination of extreme levels of extracellular vesicles: tissue factor activity in patients with severe COVID-19
por: Guervilly, Christophe, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_29br0bpb1fo3nhaie12bq2s56m